Sign In
Buy HEPA
$0.0600
-0.0030 (-4.76%)
At Close: Jun 03, 2026
Dow Surges 2.3% as Boeing Begins Testing the 737 Max
12:00am, Tuesday, 30'th Jun 2020
Stocks Analysis by Zacks Investment Research covering: Boeing Co, Ciena Corp, Lennar Corporation, Verizon Communications Inc. Read Zacks Investment Research's latest article on Investing.com
EDISON, NJ / ACCESSWIRE / June 29, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease ari
Intercept Drops as FDA Refuses Speedy Approval of Liver Drug - BNN Bloomberg
08:20pm, Monday, 29'th Jun 2020
Intercept Pharmaceuticals Inc. shares plummeted Monday as U.S. regulators dashed hopes for an accelerated approval of what investors thought would be the first medicine to treat tens of millions of pe
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
08:15pm, Monday, 29'th Jun 2020
EDISON, NJ / ACCESSWIRE / June 29, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease ari
Intercept Shares Tumble on NASH Disappointment
08:05pm, Monday, 29'th Jun 2020
Questions about drugs aimed at treating the liver disease have been bubbling up for months.
Oil futures climb, with U.S. prices up more than 3%
06:40pm, Monday, 29'th Jun 2020
Oil futures climbed on Friday, with U.S. prices up by more than 3%, finding support from some recovery in energy demand, even as that recovery is threatened...
Xconomy: FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data
06:08pm, Monday, 29'th Jun 2020
The FDA has rejected an Intercept Pharmaceuticals drug developed to treat the fatty liver disorder nonalcoholic steatohepatitis, more commonly referred to
FDA turns down Intercept’s long-anticipated NASH drug
05:06pm, Monday, 29'th Jun 2020
The FDA has requested additional data from the company's clinical trial. Intercept's CEO expressed disappointment at the decision, saying the agency had not communicated that the drug, obeticholic aci
Ecco perché oggi il prezzo delle azioni Intercept è crollato del 40% | Invezz
04:26pm, Monday, 29'th Jun 2020
Le azioni di Intercept Pharmaceuticals, Inc (Nasdaq: ICPT) sono precipitate di oltre il 40% dopo che la Food and Drug Administration (FDA) statunitense ha rifiutato di approvare il farmaco dell’azie
Here’s why Intercept stock price collapsed 40% today | Invezz
03:37pm, Monday, 29'th Jun 2020
Shares of Intercept Pharmaceuticals, Inc (Nasdaq: ICPT) plunged over 40% after the U.S. Food and Drug Administration (FDA) declined to approve the firm’s therapy for liver disease. As a result, Inte
FDA Tells Intercept Pharmaceuticals No on Its NASH Drug Candidate -- for Now | The Motley Fool
02:55pm, Monday, 29'th Jun 2020
The pharmaceutical company's attempt to get obeticholic acid approved for the lucrative non-alcoholic steatohepatitis market has hit a (perhaps temporary) roadblock.
Why Intercept Pharmaceuticals Stock Is Crashing Today | The Motley Fool
02:49pm, Monday, 29'th Jun 2020
Shares are taking a step back after the FDA rejected the company's NASH candidate.
Genfit : L'américain Intercept, rival de Genfit, se prend à son tour les pieds dans le tapis
02:32pm, Monday, 29'th Jun 2020
(BFM Bourse) - L'agence américaine du médicament a refusé d'homologuer l'Ocaliva (acide obéticholique) d'Intercept pour le traitement de la fibrose du foie …
U.S. FDA declines to approve Intercept's NASH therapy; shares plunge
12:58pm, Monday, 29'th Jun 2020
The U.S. Food and Drug Administration declined to approve Intercept Pharmaceuticals Inc's therapy for a progressive liver disease, the company said on Monday, sending its shares down 37% before the be
FDA rejects Intercept Pharma's drug for fatty liver disease
12:28pm, Monday, 29'th Jun 2020
Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat the fatty liver disease known as NASH.
